• BioBoom

Antibodies Is How We Get Back To Normal

Updated: Oct 6, 2020

The Biotech landscape has been slowly shifting awareness to the likes of Antibodies & Therapeutics, especially after the President was treated with Monoclonal Antibodies, everyone who was not aware, is now curious. I write this as the President is sick, and let's hope he makes it out with a renewed respect for the virus. I mean, he did post a video stating

" I learned about covid, I learned it by really going to school, this is the real school, this isn't the read the book school, and I get it, I understand it, and it's a very interesting thing and I'm going to be letting you know about it.

My interpretation of this is that he has first hand experienced being treated with Monoclonal Antibodies, and for the sake of this article, we will focus on that, although he was treated with a long list of other therapeutics. This is important as the President has power to sway funding attention towards companies that are focused on treating the virus using Neutralizing Antibodies.

Renewed Attention On Sorrento Therapeutics

Sorrento Therapeutics has been known as the biotech company with the most potent neutralizing antibody in STI-1499. Not only that, just recently Sorrento Therapeutics has come out with a new antibody named STI-2020.

The press release states "Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) released preclinical data reporting on COVI-GUARD™ (STI-1499) and COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 as well as a D614G virus variant infection in a preprint publication, which can be found at

{}. Both STI-1499 and STI-2020 demonstrated potent neutralizing activities against SARS-CoV-2 virus infection in preclinical models. STI-1499 nAb has been cleared by the FDA for a Phase 1 clinical trial in hospitalized COVID-19 patients. STI-2020 is an affinity-matured version of the COVI-GUARD nAb and has demonstrated a greater than 50-fold increase in potency in in vitro experiments." An affinity-matured version of the COVI-GUARD nAB is breakthrough that increases potency 50-fold! Not only is it affinity matured, but it 100% neutralizes the virus in animal studies. This breakthrough is to not be forgotten. I would take a not of this for future referenc. What is affinity matured? In immunology, affinity maturation is the process by which TFH cell-activated B cells produce antibodies with increased affinity for antigen during the course of an immune response. With repeated exposures to the same antigen, a host will produce antibodies of successively greater affinities. A secondary response can elicit antibodies with several fold greater affinity than in a primary response. Affinity maturation primarily occurs on surface immunoglobulin of germinal center B cells and as a direct result of somatic hypermutation (SHM) and selection by TFH cells.[1] In preclinical cell-based assay, both STI-1499 and STI-2020 have shown 100% in vitro neutralization of SARS-CoV-2 at concentrations of 6 µg/ml and 78 ng/ml, respectively. The neutralization activity at these concentrations protected against both SARS-CoV-2 and the highly contagious Spike D614G isolate.

Dr. Slobodan Paessler’s laboratory at the University of Texas Medical Branch at Galveston (UTMB) has generated promising preclinical animal data for STI-1499 and STI-2020 nAbs in a Syrian golden hamster model infected with SARS-CoV-2. A few highlights of the data from the most recent STI-2020 study:

Forward Looking Projections

This section is my forward looking thesis from back in May coming to fruition, with some newly added details. Monoclonal neutralizing antibodies will now be the focus of the White House and FDA. This new focus will drive the FDA to fast track all neutralizing antibody trials, potential funding, and early EUA's. Regeneron will be submitting an EUA for REGN COV2, and like I have mentioned before, Sorrento Therapeutics will follow the same path. It took Regeneron approximately one month to complete a phase 1b and move into a phase 2/3. I expect Sorrento to have safety/efficacy results from phase 1b in mid to late October. Now here is a curveball. Sorrento Therapeutics tonight released that they will be hosting a research and development. Check out the agenda.


The curveballs are, STI-2030 (Salicyn-30: a novel, orally available, small molecule inhibitor against SARS-CoV-2 infection with differentiated Mode of Action with potential for pan-coronaviruses, is discovered and selected for IND-enabling studies) & STI-2099 (encoded plasmid DNA expressing STI-2020 nAb for intra-muscular administration).

*As for STI-2030, we have very little information on the actual drug, but I have an article for you to read and a photo explaining the general scientific concept of Small molecule inhibitors.

STI-2099 is the nAB that I personally have been excitedly awaiting. Remember the acquisition of Smartpharm? STI-2099 is what they have been working on and finally made it into the pipeline. A gene encoded (smart) nAB! No pun intended. It is finally here, so if you have not visited the SmartPharm website, I highly you encourage you do, as it breaks down the method to the madness. This acquisition adds value to the company, and I expect more gene encoded nAbs to pop up not only for covid 19, but for cancer as well. Stay tuned on the breakthroughs that Sorrento Therapeutics makes with this new gene encoded technology.

Sorrento is Active

These next few weeks are action packed! First , on october 13th they will be hosting a R&D conference that you can login and participate live. Time frame of 90 minutes, showcasing the most comprehensive Covid 19 pipeline in the industry. Sorrento Therapeutics has fearlessly constructed a pipeline that includes testing, early, mid , and stage treatments for covid 19. Not only that, they have a cancer/immunotherapy pipeline that is second to none. You see that ADNIC in the immunotherapy pipeline? Don't sleep on that, ADNIC is the technology used in targeting tumors, but can also be used in targeting different tissues in the body in order to deliver antibodies directly to organs like the lungs, liver, kidney etc..

🤫 Don't tell the bears

Three days after the R&D conference, there will be a shareholder meeting. The most significant vote of that agenda, will be to vote Dr Ji's milestone awards package. I mentioned in my last blog, that Dr Ji will be doing everything possible in order to earn those votes. That will make him the Elon Musk of Small Biotech companies, and motivate to increase share price!

Def 14 a

I Appreciate all the support and followers of this blog. Don't forget to sign up for the free newsletter. It sends these blogs directly to you when they are published. Also don't forget to follow me on StockTwits & Twitter for daily commentary:

2,250 views0 comments

Recent Posts

See All